Open Access Policy

Open Access Policy for "Journal of Drug Delivery and Biotherapeutics"

At "Journal of Drug Delivery and Biotherapeutics," we are unwavering in our commitment to advancing knowledge in the field of pharmaceutical and biomedical sciences by promoting open and unrestricted access to research. Embracing principles of openness, transparency, and collaboration, we have established the following Open Access Policy:

Open Access Publication:

"Journal of Drug Delivery and Biotherapeutics" is an open access journal, ensuring that all articles published in the journal are freely accessible to the public without any subscription or paywall barriers. This inclusive approach enables researchers, practitioners, students, and the broader public to access and benefit from the latest research findings in the pharmaceutical and biomedical field.

Author Retention of Copyright:

We firmly believe in authors' rights to their own work. Therefore, when authors choose to publish their articles in "Journal of Drug Delivery and Biotherapeutics," they retain copyright ownership and grant the journal a non-exclusive license to publish the article. This empowers authors to freely share and disseminate their research while duly acknowledging the journal as the original place of publication.

Creative Commons License:

To facilitate the broadest possible dissemination and use of published articles, all content in "Journal of Drug Delivery and Biotherapeutics" is published under a Creative Commons Attribution License (CC BY). This licensing framework allows users to copy, distribute, transmit, and adapt the work, provided they offer appropriate credit to the original authors and source of publication.

Archiving and Preservation:

Recognizing the significance of long-term preservation and accessibility of research, "Journal of Drug Delivery and Biotherapeutics" is committed to archiving all published articles and ensuring their enduring availability. We collaborate with reputable digital archives and repositories to safeguard our content and assign persistent identifiers to each article, simplifying citation and referencing.

Author Fees and Funding:

To sustain the open access model and defray the costs associated with publication, "Journal of Drug Delivery and Biotherapeutics" may require authors to pay an article processing charge (APC) upon acceptance of their manuscript. Nevertheless, we are dedicated to maintaining affordable fees and offering waivers or discounts to authors from low-income countries or those facing financial constraints. Precise details regarding APCs, waivers, or discounts will be prominently communicated on our journal's website.

Ethical Considerations:

"Journal of Drug Delivery and Biotherapeutics" upholds stringent ethical standards. We expect authors to adhere to the highest ethical principles while conducting and reporting their research. Any form of unethical conduct, including plagiarism, fabrication, or falsification, is rigorously prohibited. Additionally, we insist on authors following appropriate guidelines for obtaining informed consent and safeguarding participant confidentiality.

Data Sharing:

We actively encourage authors to share their research data and make it openly accessible whenever feasible. Data sharing enhances research reproducibility, transparency, and impact. We urge authors to deposit their datasets in recognized repositories or provide comprehensive information enabling readers to access and utilize the data that underpins their published articles.

By enacting this Open Access Policy, "Journal of Drug Delivery and Biotherapeutics" aspires to foster a global exchange of knowledge, expedite scientific progress, and offer valuable research freely accessible to all stakeholders—benefiting researchers, practitioners, policymakers, and the public keen on pharmaceutical and biomedical sciences.